Ningbo Menovo Pharm Co Ltd (603538) - Total Assets
Based on the latest financial reports, Ningbo Menovo Pharm Co Ltd (603538) holds total assets worth CN¥4.60 Billion CNY (≈ $672.79 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 603538 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Ningbo Menovo Pharm Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Ningbo Menovo Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Check Ningbo Menovo Pharm Co Ltd (603538) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Ningbo Menovo Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Ningbo Menovo Pharm Co Ltd's total assets of CN¥4.60 Billion consist of 47.1% current assets and 52.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 14.5% |
| Accounts Receivable | CN¥364.75 Million | 7.5% |
| Inventory | CN¥858.72 Million | 17.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥234.09 Million | 4.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Ningbo Menovo Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Ningbo Menovo Pharm Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ningbo Menovo Pharm Co Ltd's current assets represent 47.1% of total assets in 2025, an increase from 45.8% in 2011.
- Cash Position: Cash and equivalents constituted 14.5% of total assets in 2025, down from 18.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 13.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 17.7% of total assets.
Ningbo Menovo Pharm Co Ltd Competitors by Total Assets
Key competitors of Ningbo Menovo Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Ningbo Menovo Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.45 | 1.21 | 1.66 |
| Quick Ratio | 0.80 | 0.65 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥635.28 Million | CN¥334.85 Million | CN¥640.41 Million |
Ningbo Menovo Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ningbo Menovo Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.34 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | CN¥4.85 Billion |
| Market Capitalization | $1.35 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ningbo Menovo Pharm Co Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ningbo Menovo Pharm Co Ltd's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ningbo Menovo Pharm Co Ltd (2011–2025)
The table below shows the annual total assets of Ningbo Menovo Pharm Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.85 Billion ≈ $710.06 Million |
+4.32% |
| 2024-12-31 | CN¥4.65 Billion ≈ $680.62 Million |
+5.15% |
| 2023-12-31 | CN¥4.42 Billion ≈ $647.30 Million |
+0.09% |
| 2022-12-31 | CN¥4.42 Billion ≈ $646.71 Million |
+10.45% |
| 2021-12-31 | CN¥4.00 Billion ≈ $585.54 Million |
+30.65% |
| 2020-12-31 | CN¥3.06 Billion ≈ $448.17 Million |
+17.17% |
| 2019-12-31 | CN¥2.61 Billion ≈ $382.51 Million |
+15.10% |
| 2018-12-31 | CN¥2.27 Billion ≈ $332.33 Million |
+50.03% |
| 2017-12-31 | CN¥1.51 Billion ≈ $221.50 Million |
+58.45% |
| 2016-12-31 | CN¥955.29 Million ≈ $139.79 Million |
+15.42% |
| 2015-12-31 | CN¥827.64 Million ≈ $121.11 Million |
-14.40% |
| 2014-12-31 | CN¥966.89 Million ≈ $141.49 Million |
+11.82% |
| 2013-12-31 | CN¥864.69 Million ≈ $126.53 Million |
+3.98% |
| 2012-12-31 | CN¥831.58 Million ≈ $121.69 Million |
+17.13% |
| 2011-12-31 | CN¥709.97 Million ≈ $103.89 Million |
-- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more